Scilex Holding Company

77 articles about Scilex Holding Company

• Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool

  4/9/2024

  Scilex Holding Company announced launching of co-pay programs for both ZTlido® and ELYXYB® with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0.

• Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed

  3/20/2024

  Scilex Holding Company announced it will seek approval from the FDA for the modification of the Gloperba® label to include its ability to utilize dosing flexibility of liquid formulation to address unmet medical needs and provide specific dosing guidance to patients with renal impairment as set out below:

• Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB®

  3/18/2024

  Scilex Holding Company today announced that it has responded to questions on the product composition in the ELYXYB patent from Health Canada’s Office of Patented Medicines and Liaison (OPML) during review of a New Drug Submission (“NDS”) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB® for acute treatment of migraine with or without aura in Canada.

• Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults

  3/5/2024

  Scilex Holding Company announced expected plans to launch Gloperba, its novel liquid colchicine formulation, in the first half of 2024 with a launch price of $595 per 150ml bottle.

• Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

  3/5/2024

  Scilex Holding Company announced the closing of its previously announced public offering of 5,882,353 shares of common stock of the Company and accompanying common warrants to purchase up to 5,882,353 shares of common stock, at a combined public offering price of $1.70, less underwriting discounts and commissions.

• Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

  3/4/2024

  Scilex Holding Company announced the launch of its redesigned website showcasing the Company’s growing portfolio of non-opioid pain management therapeutics.

• Scilex Holding Company Announces $10 Million Bought Deal Offering

  2/29/2024

  Scilex Holding Company announced that it has entered into an underwriting agreement with Rodman & Renshaw LLC and StockBlock Securities LLC, as underwriters, pursuant to which the underwriters have agreed to purchase on a firm commitment basis 5,882,353 shares of common stock of the Company and accompanying common warrants to purchase up to 5,882,353 shares of common stock, at a price to the public of $1.70 per share and accompanying Common Warrant, less underwriting discounts and commissions.

• Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S.

  2/28/2024

  Scilex Holding Company announced a major initiative with a leading national pharmacy chain to stock GLOPERBA® in most of their stores throughout the U.S. GLOPERBA®, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., is expected to launch in the U.S. in first half of 2024.

• Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)

  2/27/2024

  Scilex Holding Company announced acceptance of an abstract for poster and oral presentation at the 2024 Annual Meeting of the American Academy of Pain Medicine which will take place on March 7-10, 2024 in Scottsdale, Arizona.

• Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met

  2/26/2024

  Scilex Holding Company announced ZTlido® has reached three major milestones since it launched in October 2018.

• Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

  2/20/2024

  Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”) today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

• Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

  1/2/2024

  Scilex Holding Company provided certain preliminary unaudited financial results for gross and net sales for the fiscal year ended December 31, 2023, based on currently available information.

• Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

  12/20/2023

  Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that according to prescription data from Symphony Health, ZTlido® is the most prescribed non-opioid, branded pain treatment prescribed by pain specialists.

• Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.

  12/15/2023

  Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced a national leading pharmacy chain to stock ELYXYB®.

• Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three National PBMs (Pharmacy Benefit Manager) for its Medicare Population

  12/12/2023

  Scilex Holding Company announced that it has signed an insurance coverage agreement for ELYXYB® with a national PBM, for their Medicare population potentially expanding coverage of ELYXYB®.

• Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State

  12/6/2023

  Scilex Holding Company announced that one Midwestern and one Southern State voted to add ZTlido® as a preferred agent to their Medicaid Preferred Drug Lists effective as of January 1, 2024.

• Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee

  12/4/2023

  Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the State of Tennessee added ZTlido® as a preferred agent to the Medicaid Preferred Drug List effective as of October 1, 2023.

• Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan

  11/30/2023

  Scilex Holding Company announced the successful completion of a Good Manufacturing Practices inspection by the U.S. Food and Drug Administration of the enhanced manufacturing facility of Oishi Koseido Co., Ltd. for ZTlido® located in Tosu, Saga, Japan.

• Scilex Holding Company announces pharmacy initiative to stock ELYXYB® in over 500 stores for a leading pharmacy chain in the U.S.

  11/28/2023

  Scilex Holding Company announced that it has entered into an agreement with a leading pharmacy chain in the U.S. to stock ELYXYB® in over 500 stores which do not currently stock ELYXYB®.

• Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido® (lidocaine topical system)

  11/17/2023

  Scilex Holding Company today announced that the U.S. Patent and Trademark Office has issued a second new patent, No. 11,786,455 (the ”Patent”).